GENETIC TECH LTD-SP ADR (GENE)

Appendix 4C & Quarterly Business Update – March 2024

Launching our most comprehensive test and expanding into new global markets

Appendix 4C & Quarterly Business Update – March 2024

Quarterly Business Update; Launching our most comprehensive test and expanding into new global markets...

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Genetic Technologies Announces Closing of $2 Million Registered Direct Offering...

Genetic Technologies Announces $2 Million Registered Direct Offering

Genetic Technologies Announces $2 Million Registered Direct Offering

Genetic Technologies Announces $2 Million Registered Direct Offering...

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

GTG to pilot GeneType in Breast Screen centers across the U.S.

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in...

GTG Global Collaborations and Innovation Update

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare